Esophageal Balloon Electrode Catheter for Transthoracic Recording of His-Bundle Potential with Transesophageal Atrial Pacing

To evaluate the influence of transesophageal atrial pacing of the transthoracic His potential identification, we combined signal-averaged ECG with transesophageal atrial pacing with low threshold for pacing averaging ECG recording. A tripolar 10 French esophageal balloon electrode catheter, with one cylindrical electrode on the tip of the catheter and two balloon electrodes on the cardiac side of the catheter, used in 53 patients, allowed a painless transesophageal atrial pacing and a high signal to noise distance in the signal-averaged ECG. Transesophageal atrial pacing allowed in 37 of 53 patients an identification of His potential by increasing the distance between the end of the atrial potential and the onset of the His potential in the pacing averaging ECG. The esophageal balloon electrode catheter allowed a painless transesophageal atrial pacing with low threshold for atrial capture during a long pacing time and a high signal to noise distance in the pacing averaging ECG. The increasing of the heart rate with transesophageal atrial pacing allowed the transthoracic identification of the His potential in the pacing averaging ECG.     

Transesophageal Atrial Pacing—Stimulation and Discomfort Thresholds: The Role of Electrode Configuration and Pulse Width

A balloon catheter with six electrodes has been developed for transesophageal atrial stimulation of the human heart. Introduction is easy and its positioning is simple with the help of six unipolar atrial electrograms. In a group of 20 healthy volunteers, stimulation and discomfort thresholds (intolerable discomfort) were measured for three levels of pulse widths (12, 16, and 20 msec) and for five electrode configurations. Stimulation thresholds were below discomfort thresholds in each case. The stimulation threshold depended on pulse width and not on electrode configuration. The discomfort threshold, however, depended on the electrode configuration and not on the pulse width. A moderate but potentially important increase of the ratio between stimulation threshold and discomfort threshold could be achieved by combining a long pulse width (20 msec) and avoiding the largest distance between the active (cathode) and the passive (anode) electrode. Transesophageal atrial stimulation promises to be a practical noninvasive tool for the termination of regular supraventricular tachycardias, basal electrophysiological studies, and controlled acceleration of the heart rate in the study of myocardial ischemia.     

Termination of Spontaneous Atrial Flutter by Transesophageal Pacing

Transesophageal atrial pacing using the constant-rate technique was performed in 26 patients presenting with spontaneous atrial flutter (atrial cycle length between 180 and 270 ms). All but one patient had been treated with one or more antiarrhythmic agents (digoxin, quinidine, procainamide, propranolol, verapamil, diltiazem, and propafenone) within the previous 12 hours. Transesophageal atrial pacing at cycle lengths between 80 and 180 ms was successful in terminating atrial flutter in 22 patients: immediate reversion to sinus rhythm in 16, following transient sinus pause in one, following a brief period of atrial fibrillation in three, and following longer periods of atrial fibrillation in another two. No post-conversion ventricular arrhythmia and no other complications were observed. All patients experienced only a mild burning discomfort during the procedure. It is concluded that atrial pacing via the esophagus is a safe and noninvasive technique of terminating spontaneous atrial flutter. The effectiveness of this technique is comparable to endocardial or epicardial atrial pacing.     

Transesophageal Atrial Pacing Complications in Patients Suspected of Tachy-Brady Syndrome

RACZAK, G., ET AL.: Transesophageal Atrial Pacing Complications in Patients Suspected of Tachy-Brady Syndrome. The clinical effects of transesophageal atrial pacing (TAP) were assessed in 308 patients. Indications for TAP included evaluation for pacemaker implantation in patients suspected of sinus node dysfunction and determination of the suitable type of pacemaker. Most patients underwent program stimulation including rapid as well as burst stimulation. In one patient, following the study, cerebral arterial embolism occurred, most likely secondary to an induced arrhythmia. That was the only single case of permanent consequences following TAP. Additionally, one patient was accidentally stimulated in the ventricle using low voltage electric current that induced ventricular fibrillation. This was promptly reversed with defibrillation. Twenty-six patients in whom an arrhythmia was previously induced, required medical therapy, two of whom required cardioversion, and 24 required drug therapy, subsequent to clinical intolerance of the arrhythmia. No lethal complications occurred.     

Impedance to Transesophageal Atrial Pacing: Significance Regarding Power Sources

Transesophageal stimulation is an expeditious method of atrial pacing. Using pulse widths of 10 msec results in reduction of current requirement to values that are usually less than 15 mA. An unknown variable in transesophageal atrial pacing has been impedance. In this study, we investigated the impedance to transesophageal atrial pacing in ten patients using a stimulator with a 63 V power source capable of delivering constant current to 20 mA against an impedance of 2,000 ohms. A bipolar electrode was used to deliver stimuli with a current of 15 mA. Voltage across a known resistance and current were measured on an oscilloscope and the impedance was calculated. Pacing thresholds were also performed and ranged from 6.2 to 16.5 mA (mean 9.4 +/- 2.9 mA, SD). Impedance varied between 720 and 2,670 ohms (mean 1,750 +/- 540 ohms). The stimulator used to measure impedance in man and two other commercially available stimulators were bench tested against known resistances of 500 to 2,000 ohms. The other stimulators with power sources of 12.5 and 15 V had attenuation of the delivered current at resistances of between 1,000 and 2,000 ohms. Thus, this study has demonstrated that transesophageal atrial pacing incurs impedances two to five times greater than incurred with intracardiac pacing leads. Therefore stimulators with high power sources are required to deliver the programmed current against these impedances.     

Bedside Termination of Sustained Ventricular Tachycardia by Transesophageal Atrial Pacing

Transesophageal atrial pacing was used to terminate hemodynamically stable sustained monomorphic ventricular tachycardia in two patients. The procedure was performed at the bedside, no anesthesia was required, there were no complications, and one of the patients went home after the procedure was performed. This method should be considered prior to using direct current cardioversion in patients with hemodynamically stable sustained monomorphic ventricular tachycardia.     

Combined Transesophageal Left Atrial Pacing and Antiarrhythmic Therapy in the Treatment of Atrial Flutter

In order to terminate atrial flutter (AF) overdrive transesophageal left atrial pacing (TELAP) was performed in 760 patients with paroxysmal AF. There were 315 women and 415 men (mean age 59 years). In 260 patients, TELAP was used in an outpatient setting. Approximately half of the patients (51 %) had coronary artery disease and/or arterial hypertension, and 23% of the patients had no structural heart disease. The duration of AF ranged between 1 hour and 1 month. TELAP was performed in 312 patients without any antiarrhythmic drug (AAD) administration (group I) and in 448 patients after administration of AAD (procainamide and/or amiodarone) in conventional doses (group II). TELAP resulted in immediate return of sinus rhythm in 85 patients (27%) of group I and in 222 patients (50%) of group II (P < 0.001). TELAP converted AF to atrial fibrillation (AFIB) in 185 of group I and in 214 (48%) of the group II patients (P < 0.01). In addition, within 1–2 days after TELAP AFIB converted to sinus rhythm spontaneously or after AAD in 87 patients of group I (28%) and in 84 (19%)of the group II patients (P < 0.01). In general, sinus rhythm was restored in 172 (55%) of the group I and in 306 (68%) of the group II patients (P < 0.005). AF was converted to AFIB in 98 (31 %) of the group I and in 130 (29%) of the patients in group II patients (NS). TELAP was ineffective in 42 (13.5%) of the group I and in 12 (3%) of the group II patients (P < 0.001). TELAP was an effective noninvasive method for the treatment of recent onset AF. Our experience showed that after TELAP, sinus rhythm was restored in most of the patients with paroxysmal AF within 1–2 days. In some patients TELAP converted AF to AFIB, making it easier to control the heart rate with AAD. Treatment with AAD before TELAP increased its effectiveness.     

经食管心房调搏插管中最佳起搏位置的参数分析

目的　通过对起搏多参数分析以寻找最佳起搏位置 ,把病人的痛苦程度降到最小。方法　 90 7例经食管心房调搏 (TEAP)的病人 ,分析身高、插管深度、食管导联P波振幅及方向和起搏阈值 ,对统计数值行相关分析。结果　食管电极导管插入的深度与病人的身高有显著的相关性 (P <0 .0 0 1) ;食管导联P波振幅的高低与起搏阈值呈负相关 (P <0 .0 0 1) ;3种不同P波形态与起搏阈值组间无差异 (P >0 .0 5 )。结论　病人的身高可预测插管的深度 ;食管导联P波振幅越大 ,所用起搏阈值则越小 ,而与P波形态无关     

Diagnostic Value of Synchronized Transesophageal Atrial Pacing

Synchronized transesophageal atrial pacing (single and double extrastimuli) was used in 137 patients with various tachycardias inducible by atrial pacing during transesophageal electrophysiological study (EPS). This pacing mode in five patients initiated atrioventricular tachycardias with ipsilateral bundle branch block not seen when using other pacing modes. During the tachycardia, single or double extrastimuli caused ipsilateral bundle branch block disappearance in two patients with atrioventricular tachycardia, and changed AV activation ratio in one patient with atrioventricular junctional reentrant tachycardia. This pacing mode causes very little discomfort, what is important in children, and enhances diagnostic abilities of transesophageal EPS. So, this pacing mode should be used routinely as one of the steps of transesophageal EPS.     

Type II Atrial Flutter Interruption with Transesophageal Pacing: Use of Propafenone and Possible Change of the Substrate

Type II atrial flutter (AFII) is an arrhythmia which usually cannot be interrupted by atrial pacing: the underlying mechanism is considered to be a leading circle without an excitable gap. We investigated whether the administration of propafenone, an antiarrhythmic drug, which primarily decreases conduction velocity, has a beneficial effect on AFII interruption using transesophageal pacing. Twelve patients with an AFII were randomized into 2 groups in which pacing was performed without treatment (group A) or two hours after the administration of 600 mg of oral propafenone (group B). Sinus rhythm was attained in 0 of 6 patients in group A and in 4 of 6 patients in group B (P < 0.05). The baseline mean cycle length was the same in both groups (175 ± 7 (A) vs 168 ± 8 ms (B); it lengthened significantly after the administration of propafenone (219 ± 33 vs 168 ± 8 ms; P < 0.05). Propafenone did not significantly lengthen the cycle in the two patients in whom interruption of the arrhythmia was impossible. Our data show that propafenone has a facilitating effect on atrial pacing only when it significantly prolongs the cycle length of the arrhythmia, possible expression of a conversion of AFII into type I, with an anatomical substrate and an excitable gap allowing arrhythmia capture and interruption. In the two patients in whom sinus rhythm was not restored, the absence of a direct dependence of the cycle length on the change in conduction velocity induced by propafenone may be explained by the persistence of a functionally determined circuit, resistant to atrial pacing.     

Electrophysiological Evaluation of Tachycardias Using Transesophageal Pacing and Recording

VOLKMANN, H., ET AL: Electrophysiological Evaluation of Tachycardias Using Transesophageal Pacing and Recording. Programmed electrical stimulation of the heart to initiate and terminate tachycardia has been useful in the evaluation of supraventricular and ventricular tachyarrhythmias. A wide use of these procedures, however, failed because of the expense of the invasive approach as well as the lack of physician experience in smaller hospitals. These disadvantages of the invasive proceeding can be abolished by transesophageal pacing. In our study, supraventricular tachycardias were initiated by programmed transesophageal atrial stimulation in 251 patients [AV node reentry in 75 patients, orthodromic AV reciprocating tachycardia using accessory pathway in 97 patients, antidromic AV reciprocating tachycardia in 11 patients, and atrial reentry in 39 patients). The stimulation protocol included one and two extrastimuli during sinus rhythm and after a pacing drive at different cycle lengths. The electrophysiological mechanism of tachycardias was determined by surface ECG, VA interval (esophageal lead), initiation mode at programmed transesophageal stimulation and by behavior of AV conduction and refractoriness. In 29 patients the mechanism of tachycardia was not clear. Invasive electraphysiological study was done in 219 of these 251 patients. In only nine patients, the supported mechanism of tachycardia was not confirmed by invasive investigation. In 11 patients, the etectrophysiological mechanism remained uncertain. In conclusion, the noninvasive transesophageal pacing is an appropriate method for evaluation of supraventricular tachycardia. It allows serial drug testing in a simple manner for finding an effective antiarrhythmic treatment.     

A Method of Esophageal Electrogram Recording for Diagnostic Atrial and Ventricular Pacing

This study evaluates improvement of the electrogram sensed via an esophageal catheter with the sensing electrode adjacent to the stimulating electrode with and without a specialized artifact suppression system. In 100 patients (65 men and 35 women) aged 16-60 years (mean 48 years), esophageal recordings of left atrial activity were obtained during simultaneous transesophageal atrial pacing. Transesophageal ventricular pacing was performed in an additional 34 patients. Without the suppression system, ventricular paced activity, recorded from the esophagus, was not suitable for interpretation. About 10% of the atrial electrogram response could be recorded and evaluated during atrial pacing. With the stimulus artifact suppression system, interpretable recordings were obtained 100% of the time during atrial and ventricular recordings. The method described allows use of transesophageal diagnostic testing where previously only the intracardiac route was possible.     

Use of the Pill Electrode for Transesophageal Atrial Pacing

The pill electrode, which was developed for esophageal electrocardiography, has found application in transesophageal atrial pacing during procedures such as conversion of tachycardia, electrophysiologic measurement, and acceleration of heart rate to produce stress during cardiac imaging studies. This paper presents theoretical studies that examine the relationship of interelectrode distance, current level, and pulse duration to the achievement of successful capture. Theoretical results agree with our clinical findings, i.e., current levels of 25 mA are effective to sustain capture; increased pulse duration reduces current requirements; and close bipolar spacing combines efficacy with safety. Results of animal studies performed to assess the extent of esophageal burn injury reveal that current levels in excess of 75 mA are required to produce lesions in short-term (under 30 minutes) pacing, and greater than 60 mA in long-term (4 hours) pacing. These results are based on experiments using a pulse duration of 2 ms, and the current levels that produce injury will be considerably lower if longer pulse durations are used. Typical current levels and pulse durations for successful capture are presented for 46 subjects in several new clinical applications. Termination of tachycardia, basic electrophysiologic measurements, and controlled acceleration of heart rate can be performed noninvasively with this technique.     

Atrial Septal Pacing: A Method for Pacing Both Atria Simuhaneously

By pacing both atria simultaneously, one could reliably predict and optimize left-sided AV timing without concern for IACT. With synchronous depolarization of the atria, reentrant arrhythmias might be suppressed. We studied four male patients (73 ± 3 years) with paroxysmal atrial fibrillation and symptomatic bradyarrhythmias using TEE and fluoroscopy as guides; a standard active fixation screw-in lead (Medtronic model #4058) was attached to the interatrial septum and a standard tined lead was placed in the ventricle. The generators were Medtronic model 7960. The baseline ECG was compared to the paced ECG and the conduction time were measured to the high right atrium, distal coronary sinus and atrial septum in normal sinus rhytbm, atrial septal pacing, and AAT pacing. On the surface ECG, no acceleration or delay in A V conduction was noted during AAI pacing from the interatrial septum as compared with normal sinus rhythm. The mean interatrial conduction time for all 4 patients was 106 ± 2 ms; the interatrial conduction time measured during AAT pacing utilizing the atrial septal pacing lead was 97 ± 4 ms (P = NS). During atrial septal pacing, the mean conduction time to the high right atrium was 53 ± 2 ms. The mean conduction time to the lateral left atrium during atrial septal pacing, was likewise 53 ± 2 ms. We conclude that it is possible to pace both atria simultaneously from a single site using a standard active fixation lead guided by TEE and fluoroscopy. Such a pacing system allows accurate timing of the left-sided AV delay.     

Safety of Transesophageal Pacing for 24 Hours in a Canine Model

Background: Temporary epicardial pacing is often necessary following surgical correction of congenital heart disease. Epicardial pacing wires, while generally effective, can, however, become nonfunctional. Transesophageal atrial pacing (TEAP) can be a useful adjunct in this setting. The potential for esophageal damage with sustained TEAP is unknown. We assessed the safety of continuous (24 hours) TEAP by evaluating gross and histological changes to the esophagus in a canine model.
Methods: Thirteen juvenile beagle dogs were fitted with a 4-Fr multipolar catheter placed transnasally into the esophagus to a level to sustain atrial capture. Pacing was established in nine dogs for 24 hours while four control dogs had catheters but no pacing stimulus applied. Paced dogs were divided into two groups: group A (n = 5) that were euthanized immediately and group B (n = 4) that were euthanized 7 days after the pacing period. Nonpaced dogs (group C, n = 4) were treated similar to group A. Gross and histological examination of the esophageal tissue was completed.
Results: Gross and histological evidence of mild esophagitis was noted in dogs from groups A and C but not in dogs from group B. There was no evidence of esophageal stricture or fibrosis in any dog from any group.
Conclusions: TEAP did not result in permanent esophageal changes after 24 hours of stimulation. Microscopic lesions of mild erosive esophagitis, seen after 24 hours of TEAP, were absent 7 days postpacing. Mechanical irritation from the catheter cannot be ruled out as a cause of these changes.     

Atrial Pacing: Intracardiac Conduction Assessed by His Bundle Electrograms Acquired from the Permanent Atrial Electrode at Implantation

His bundle electrograms were recorded from conventional J-shaped atrial electrodes at implantation in twelve consecutive patients who had sinus node disorder. Five patients with impairment of atrioventricular conduction, received atrioventricuIar (DVI) pacemakers. His bundle recording by this method is simple and reliable, avoids the discomfort of the conventional technique, and represents a new application for the well established atrial "J" electrode.     

The Automatic Implantable Cardioverter/Defibrillator; Transesophageal Atrial Pacing Discloses the Potential for Erroneous Discharges

We report the occurrence of erroneous discharge from an implanted automatic cardioverter/defibrillator during transesophageal atrial pacing. Transesophageal pacing was performed as part of a study protocol on the inducibility of ventricular tachycardia from the atrium in patients with ischemic heart disease. At an induced heart rate of 166 beats per minute (a value just above the cut-off rate of the device), the cardioverter/defibrillator was triggered. This observation suggests that transesophageal atrial pacing could be utilized to disclose the potential for spurious discharges in the event of fast atrial rhythms in patients with the automatic implantable cardioverter/defibrillator.     

Termination of Tachycardias by Transesophageal Electrical Pacing

To evaluate the therapeutic significance of noninvasive transesophageal pacing for termination of tachycardias the method of rapid atrial or ventricular transesophageal pacing was used in 233 patients with different tachycardiac arrhythmias. We were able to terminate atrial flutter in 136 of 162 patients by transesophageal rapid atrial stimulation (conversion to sinus rhythm in 75 cases, induction of atrial fibrillation in 61 cases). Atrial tachycardias were interrupted in 17 of 23 patients (sinus rhythm in 11 cases, atrial fibrillation in six cases). AV reciprocating/AV nodal supravenrricular reentry tachycardias were terminated in 62 of 63 patients (sinus rhythm in 58 cases, atrial fibrillation in four cases). By transesophageal rapid ventricular pacing ventricular tachycardias could be terminated in ten of 15 patients. The success rate of transesophageal pacing was influenced by the pacing rate, by the type of tachycardiac arrhythmia inclusive by the type of atrial flutter and by the tachycardia's cycle length. Because the success rates are comparable with invasive technique and the procedure is simpler, the noninvasive transesophageal antitachycardiac pacing should be respected as the method of the first choice in patients with supraven-tricular tachycardias.     

Identifying Patients for Rate Responsive Atrial Pacing: A New Method for Patient Selection and Pacemaker Programming

In patients with sinus node disease (SND) and chronotropic incompetence, atrial rate adaptive stimulation (AAI, R pacing) is regarded as the most appropriate pacing mode. Since coronary artery disease is the most common etiology in these patients, we evaluated a new technique combining two-dimensional transesophageal echocardiography and atrial transesophageal pacing to detect pacing induced wall motion abnormalities and assess safe upper rate limits. Thirty-five patients were studied; 26 with and 9 without angiographic coronary artery disease. Stable atrial capture was achieved in all patients using 12 ± 3 msec pulse width and 12 ± 4 mA current strength. Sensitivity and specificity for the detection of coronary artery disease was highest for transesophageal echocardiography during pacing (sensitivity 81%, specificity 100%). Simultaneous 12-lead ECG during pacing had lower values (sensitivity 57%, specificity 75%). Pacing induced wall motion abnormalities preceded ST segment changes in all patients. Exercise stress testing showed similar values (sensitivity 62%, specificity 89%), It is concluded that simultaneous transesophageal echocardiography and transesophageal pacing is a safe and useful technique in selecting patients for AAI, R pacing and for the detection of safe upper rate limits, particularly when coronary artery disease is suspected.     

Evaluation of Transesophageal Atrial Pacing Stethoscope in Adult Surgical Patients Under General Anesthesia

Sinus bradycardia (SB) and atrioventricular functional rhythm (AVJR) commonly cause circulatory insufficiency in anesthetized surgical patients. Treatment is usually with drugs, which can be ineffective or have adverse effects. Cardiac pacing might be preferred, but the transvenous or epicardial routes are too invasive for routine use, and transcufaneous pacing fails to preserve atrial transport function, Transesophageal atrial pacing (TAP) lacks these disadvantages, yet inavailability of inexpensive products has prevented more widespread use. Therefore, a pacing esophageal stethoscope (PES) fabricated by addition of bipolar electrodes to disposable esophageal stethoscopes routinely used for intraoperative monitoring, was evaluated in 100 anesthetized adults. TAP thresholds (10-msec pulses) and hemodynamic effects of TAP as treatment for incidental SB (< 60 beats/mm) or AVJR were determined. Minimum TAP thresholds (mean ± standard error) in 48 males were 7.3 ± 0.3 mA and in 51 females were 8.5 ± 0.4 mA. Corresponding inferior alveolar ridge-to-electrode distances were 32.5 ± 0.2 and 30.4 ± 0.2 cm. For 48 patients with SB ± 60 beats/mm (54 ± 1 beats/min), TAP (81 ± 1 ppm) produced average 15, 11, and 14 mmHg increases in systolic, diastolic, and mean arterial pressure, respectively (P < 0.001). For 11 patients with AV/R (71 ± 5 beats/mm), TAP (92 ± 3 ppm) produced average 23 and 15 mmHg increases in systolic and mean arterial pressure, respectively (P < 0.05). There were no apparent complications of TAP. TAP with a PES appears practical, safe, and effective for prophylaxis and treatment of SB or AV/R in anesthetized surgical patients.